The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Exact Sciences finds that where there’s muck there’s brass, but specialisation does not work as well for Abiomed.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
The company needed a hit in its spine trial, and it claims to have got one.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.